After Astra's EsoBiotec takeover the battle for uniqueness begins.
ApexOnco Front Page
Recent articles
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
NVL-330 features among the latest crop of industry projects newly into human trials.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.